Cargando…
Bromodomain inhibitors a decade later: a promise unfulfilled?
Over the last decade, bromodomain inhibitors have emerged as a promising class of anticancer drugs. However, the clinical progress of these agents has faced significant obstacles, which precluded their regulatory approval. This editorial will review the challenges and opportunities associated with t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722711/ https://www.ncbi.nlm.nih.gov/pubmed/32989227 http://dx.doi.org/10.1038/s41416-020-01079-x |